un Pharmaceuticals holds a strong position in the Indian generics market, leading the pack in terms of operating margin and revenue growth, although the company's sales figures currently pale in comparison with larger companies. The company's domestic revenues increased by 44.9% from US$586.5m in 2011 to US$865.9m in 2012, as market shares were captured from competitors. Sun Pharmaceuticals will have to continually compete with other Indian generic manufacturers, including Ranbaxy, Dr. Reddy's and Cipla, as well as the influx of foreign generic and branded pharmaceutical companies. This rivalry, which is likely to focus on the price sensitivity of domestic consumers, could potentially decrease the company's profit margins. Nevertheless, The authors anticipates that Sun will be one to watch in 2013, as the company aims to rub shoulders with companies in the top echelon of generics manufacturing.
Mylan benefited from aggressive growth in the Indian market during 2012, as the company's generics business flourished in the country. This resulted from an increase in sales of anti-retroviral (ARV) finished dosage form (FDF) generic products, used in the treatment of HIV/AIDS. Mylan is currently one of the world's largest API manufacturers, particularly in APIs used in manufacturing generic ARV therapies for HIV/AIDS treatment. The company has total control over its supply chain, and so can effectively control cost and quality - two crucial requirements in the pharmaceuticals business.
Similarly, Teva and Sandoz are stepping up efforts to grow their revenues outside established markets. Sandoz, in particular, needs to gain ground in emerging markets, as 80% of its generic pharmaceutical sales currently come from the US and Europe
, leaving the company exposed to the current pricing pressures and budget deficits in these markets.
1 Tables & Figures
3 GlobalData BenchmarkPage: 1 2 3 Related biology technology :1
. PharmaLeaders: Innovative Mid-Cap Biotechnology Benchmark Report - Financial Benchmarking, Pipeline Assessment & Competitive Analysis of Innovative Biotechs2
. Watsons Generic Yaz(R) Receives FDA Approval3
. Watsons Generic BONIVA® 150mg Receives FDA Approval4
. ResearchMoz: Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar- Market Research Report5
. UBM Conferences Unveils Details for Upcoming Generics and Biosimilars Conference6
. Lupin Receives FDA Approval for Generic LYRICA(R)7
. Biosim Pharmaceuticals, Manufacturers of Generic ACTHAR, to Participate at Biotech Showcase 20138
. Generic Pharma Partnering Yearbook 2013 - Access to the Partnering Deals and Agreements Globally9
. Analysis of 2012 New Drug Application Approvals (NDAs) Shows Bio/Pharma Contract Manufacturers Treading Water10
. iLab Solutions Conducts Its Third Annual Core Facility Benchmarking Study11
. ISPE Conference to Benchmark and Advance Quality by Design in the Biopharmaceutical Industry